Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
U-Neuron Biomedical's Enterprise Value for the quarter that ended in Jun. 2026 was NT$742.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. U-Neuron Biomedical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-59.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
U-Neuron Biomedical EV-to-EBIT Related Terms
U-Neuron Biomedical EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for U-Neuron Biomedical's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6973 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, U-Neuron Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
U-Neuron Biomedical EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where U-Neuron Biomedical's EV-to-EBIT falls into.
U-Neuron Biomedical's current Enterprise Value is NT$1,223.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. U-Neuron Biomedical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-59.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
U-Neuron Biomedical (ROCO:6973) has a EV-to-EBIT of -20.49 as of Aug. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on U-Neuron Biomedical and its competitors. According to the industry distribution chart, U-Neuron Biomedical ranks #999999 out of 365 companies in the Biotechnology industry.
Is U-Neuron Biomedical's EV-to-EBIT too high?
U-Neuron Biomedical's current EV-to-EBIT is -20.49. Based on the distribution chart, U-Neuron Biomedical ranks #999999 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, U-Neuron Biomedical has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, U-Neuron Biomedical ranks #999999 out of 365 companies for EV-to-EBIT. This places U-Neuron Biomedical in the lower half of its industry. The industry median EV-to-EBIT is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on U-Neuron Biomedical and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. U-Neuron Biomedical's current EV-to-EBIT is -20.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
Based on GuruFocus' analysis, U-Neuron Biomedical (ROCO:6973) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.30, compared to a current price of NT$45.15 — trading 35.8% below its estimated fair value. The current EV-to-EBIT is -20.49. U-Neuron Biomedical's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current EV-to-EBIT is -20.49 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is U-Neuron Biomedical (ROCO:6973) Overvalued in 2026?
Based on GuruFocus' analysis, U-Neuron Biomedical stock appears to be undervalued.
The current stock price of NT$45.15 is trading 35.8% below its estimated GF Value™ of NT$70.30.
GuruFocus considers U-Neuron Biomedical to be Possible Value Trap.
Key valuation signals for ROCO:6973:
EV-to-EBIT: -20.49
GF Value™: NT$70.30 vs. price of NT$45.15 (35.8% below fair value)
No single metric tells the full story. See the ROCO:6973 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
36GF Score
Get the complete analysis for ROCO:6973
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6973 has been successfully added to your 
